Picture a conference room early on a weekday morning. A large screen shows a CT scan. Next to it, a pathologist’s microscope camera projects a slide stained pink and purple. About a dozen doctors sit around the table: a surgeon, two medical oncologists, a radiation oncologist, a radiologist, a pathologist, a nurse coordinator, and sometimes a geneticist or palliative care specialist. Over the next twenty minutes they’ll discuss one patient’s cancer, argue a little, agree on a plan, and move on to the next case.
That meeting is a multidisciplinary tumour board. If you’re being treated for cancer in a large hospital, there’s a good chance your case has been, or will be, discussed at one. Yet most patients never see it, and many don’t know it exists. This article explains what a tumour board is, who sits on it, which cases go to it and when, and how you can make sure your case gets the benefit.
Key Takeaways
- A tumour board is a regular meeting where several cancer specialists review a patient’s case together and agree on a recommended plan.
- It usually includes surgeons, medical and radiation oncologists, a pathologist and a radiologist, and often nurses, geneticists and palliative care doctors.
- Cases are most often reviewed at diagnosis, after surgery, when treatment isn’t working as expected, and when cancer returns.
- The board recommends. You and your doctor decide.
- You can, and should, ask whether your case has been discussed and request the written outcome.
A Plain Definition
The US National Cancer Institute describes tumour board review as a treatment-planning process where cancer doctors and other specialists meet regularly to review new and complex cases, with the goal of agreeing as a group on the best treatment plan (NCI Dictionary of Cancer Terms).
You may hear other names for the same thing: multidisciplinary team (MDT) meeting, multidisciplinary cancer conference, tumour conference, case conference or, in some Indian hospitals, simply “the board.” The idea is the same everywhere. Cancer treatment usually involves more than one type of specialist, so those specialists should decide together and not one after another.
Why One Doctor’s Opinion Isn’t Always Enough
Cancer care is split across specialties. A surgeon may naturally think first about whether a tumour can be removed. A radiation oncologist may see a case where precise radiation could avoid surgery. A medical oncologist may think chemotherapy should come first to shrink the tumour. None of them is wrong to think this way. Each brings expertise and, unavoidably, some perspective tied to their own field.
Without a tumour board, a patient might see these specialists one at a time and hear three different recommendations. The tumour board puts all those views in one room, in front of the same scans and slides, so the final plan reflects a balanced judgment. A systematic review in Cancer Management and Research found that multidisciplinary tumour boards are associated with benefits including more accurate staging, better adherence to guidelines and better coordination of care. The authors also noted limits such as time pressure and varying levels of patient involvement (PMC review).
Who’s in the Room: The Typical Roster
| Specialist | What they bring to the discussion |
|---|---|
| Surgical oncologist | Whether the tumour can be removed, which operation, and its risks |
| Medical oncologist | Chemotherapy, targeted therapy, immunotherapy, hormone therapy and the order of treatments |
| Radiation oncologist | Whether radiation helps, its technique (IMRT, SBRT, proton and others), dose and timing |
| Radiologist | Presents the scans live and comments on tumour size, nodes and spread |
| Pathologist | Presents the slides, confirms the diagnosis, grade and biomarkers |
| Nuclear medicine physician | Interprets PET-CT and other functional scans |
| Oncology nurse or coordinator | Practical issues, patient preferences, scheduling and follow-through |
| Geneticist or genetic counsellor | Inherited risk and family testing (where relevant) |
| Palliative care specialist | Symptom control and quality of life at every stage, not only at the end |
| Others, as needed | Dietitian, physiotherapist, psychologist, social worker, organ specialist (for example hepatologist or neurologist) |
Not every board has every member at every meeting. A head-and-neck board might include a dental surgeon and a speech therapist. A neuro-oncology board will include neurosurgeons and neuroradiologists.
Types of Tumour Boards
Site-specific boards
Most large hospitals run separate boards by cancer type: breast, thoracic (lung), gastrointestinal, gynaecological, genitourinary, head and neck, neuro-oncology, haematological, bone and soft tissue, paediatric. Focused boards mean every specialist in the room deals with that cancer every day.
Molecular tumour boards
A newer type that focuses on genetic test results. When sequencing finds unusual mutations, the molecular board, often with molecular pathologists and bioinformaticians, discusses whether any targeted drug or clinical trial fits. The Association of Community Cancer Centers describes these boards as centred on biomarkers and matching treatments or trials (ACCC).
Virtual tumour boards
Specialists from different hospitals join by video. In India, the National Cancer Grid, a network of cancer centres coordinated by Tata Memorial Centre, runs virtual tumour boards so that centres across the country can present difficult cases to wider panels of experts (NCG Virtual Tumor Board). A published audit of NCG virtual boards for head and neck cancers concluded that this model works well even in resource-limited settings (JCO Global Oncology).
When Is a Case Reviewed?
This is the question patients most often ask, and the answer depends on the hospital’s policy. Broadly, there are four moments when a case is likely to come to the board.
1. At diagnosis, before any treatment starts
This is the most valuable moment. Many hospitals aim to present every new cancer case, or at least every complex one, before the first treatment. Key decisions are made here: surgery first or chemotherapy first? Is radiation needed? Is the tumour operable at all?
2. After surgery, when final pathology is available
The tissue removed during surgery tells the team much more than the initial biopsy did: exact tumour size, margins and lymph node involvement. The board then decides whether you need further (adjuvant) treatment.
3. When the cancer doesn’t respond as expected
If scans show the tumour growing during treatment, or a new finding appears, the case goes back for a fresh look at options.
4. At recurrence or progression
If cancer returns after a gap or spreads, the board reconsiders the overall goal of care. Sometimes that’s another attempt at cure. Other times it’s a shift towards long-term disease control. Our articles on curative intent and disease control in advanced cancer explain those goals.
Which Cases Are Most Likely to Be Prioritised?
Where boards can’t discuss every patient, they usually prioritise cases with one or more of these features:
- Borderline operability, where surgery is possible but difficult or high-risk
- Cancers treated with combined approaches (surgery plus chemo plus radiation)
- Rare tumour types or unusual biology
- Disagreement between specialists or between pathology and imaging
- Patients with other serious health conditions that limit options
- Younger patients where fertility or long-term side effects matter a lot
- Recurrent disease or cancer that has stopped responding to treatment
- Possible inherited cancer syndromes
- Eligibility for clinical trials
What Happens During the Discussion: An Illustrative Walk-Through
The example below is a hypothetical case, simplified to show how a typical board discussion flows. It isn’t based on any real patient.
- Case presentation (about 2 minutes). The treating doctor summarises: “Fifty-four-year-old woman, rectal tumour found on colonoscopy, biopsy shows adenocarcinoma, no other major illnesses.”
- Radiology (3–4 minutes). The radiologist shows the pelvic MRI. The tumour sits close to the boundary of the tissue envelope around the rectum, with two suspicious lymph nodes. The CT chest and abdomen show no distant spread.
- Pathology (2 minutes). The pathologist confirms adenocarcinoma, moderately differentiated, and reports mismatch repair status.
- Discussion (5–10 minutes). The surgeon worries that operating first could leave cancer at the margin. The radiation oncologist suggests treatment before surgery to shrink the tumour. The medical oncologist brings up a newer sequencing approach that gives more chemotherapy before surgery. They weigh evidence, guidelines and the patient’s own preferences, which the coordinator passes on.
- Recommendation (1 minute). The board records an agreed plan, for example treatment before surgery followed by reassessment imaging, and notes who will discuss it with the patient.
The whole case might take fifteen to twenty minutes. Simple cases move faster and complex ones take longer.
Does the Board Make the Final Decision?
No. This point is important. The tumour board makes a recommendation. Your treating doctor then talks it through with you, and you decide together. You can ask questions, raise concerns, choose between reasonable options, or decline a treatment. The board is there to inform your decision, not to replace it.
How to Ask Whether Your Case Has Been Discussed
You don’t need special permission to ask. These simple questions work in any hospital, in India or anywhere else:
- “Has my case been presented at a tumour board?”
- “Which specialties were present?”
- “Was there any disagreement, and what were the alternatives discussed?”
- “Can I have a copy of the tumour board note or recommendation?”
- “If my case hasn’t been discussed yet, can it be before treatment starts?”
A written board note is also a useful document if you later seek a second opinion. It’s one of the records we suggest sending in our checklist on records to send for a cancer second opinion in India.
Tumour Boards for International Patients in India
If you’re travelling to India for cancer care, the tumour board often meets after your first round of local tests. Expect the hospital to:
- Review your outside reports and, ideally, your slides and scans (see what happens when a hospital rechecks your biopsy).
- Repeat or add any tests needed to complete staging.
- Present your case at the next scheduled board meeting for your cancer type.
- Share the agreed plan with you, often through the international patient desk and your coordinator.
Board meetings usually happen weekly for each cancer type, so your arrival timing can affect how quickly you get a plan. Ask your coordinator which day your relevant board meets. If you arrive the day after it, you may wait almost a week for the next one. Planning around this can save you hotel nights and stress. Our article on treatment plan changes after arriving abroad explains why the plan sometimes shifts once the board has met. Reading about planning a medical trip with multiple specialists can also help.
Limitations Worth Knowing
Tumour boards are valuable but not perfect.
- Time pressure. Busy boards may discuss twenty or more cases in a session. Complex cases deserve more time than they sometimes get.
- Patient voice can be missing. The patient is rarely in the room, so preferences have to be passed on accurately by the treating doctor or nurse.
- Quality varies. MD Anderson notes that tumour boards are now standard at accredited cancer centres, but in some places they can become more of a formality than a real decision forum (MD Anderson Cancerwise).
- Incomplete information. If scans or slides from an outside hospital weren’t available, the discussion rests on second-hand reports.
Knowing these limits helps you ask better questions. You can’t sit in on the meeting, but you can make sure the board gets complete information and that your preferences are recorded.
Signs a Hospital Takes Its Tumour Boards Seriously
When you’re comparing cancer centres, in India or anywhere else, the quality of the tumour board is one of the better quality signals available to you. Some indicators to ask about:
- Separate boards for each major cancer type, not one general meeting
- A pathologist and radiologist who present original material live
- Written, signed recommendations placed in the patient’s file
- A policy of discussing every new patient (or every complex one) before treatment
- Participation in external networks such as the National Cancer Grid
- Recognised accreditation. Our guide on how to verify Indian hospital accreditation explains what NABH and JCI labels mean.
You can also browse our overview of top oncologists in India and the best countries for cancer treatment to see how leading centres compare.
Tumour Boards and Clinical Trials
One benefit of tumour boards that’s easy to miss is access to research. When specialists review a case together, someone often knows of a clinical trial the patient might qualify for. That’s especially likely at academic centres and in molecular tumour boards. Trials aren’t right for everyone, and eligibility rules can be strict, sometimes including restrictions on foreign nationals or on patients who can’t stay for long-term follow-up. Still, it’s worth asking your doctor: “Did the board consider any clinical trials for me?” Even if the answer is no today, it keeps the option on the table for later.
Do Tumour Boards Actually Improve Outcomes?
It’s a fair question. The evidence is encouraging but mixed. Studies consistently link multidisciplinary review with more complete staging, better adherence to treatment guidelines and, in some cancers, changes to the initial plan in a meaningful share of cases. Showing a direct survival benefit has been harder, because tumour boards are usually one part of a wider package of quality care. That makes their individual effect difficult to separate out. The reasonable conclusion, reflected in systematic reviews, is that well-run boards improve how decisions are made, and that the quality of the discussion matters more than whether a meeting simply takes place. For patients, the practical lesson is to make sure your case is discussed with complete information, and to ask what the board concluded.
A Short Glossary of Board Terms
Board notes can be hard to read for someone outside medicine. These are the words that come up most often:
- Upfront surgery: operating as the first treatment, before any chemotherapy or radiation.
- Neoadjuvant: treatment given before the main treatment (usually before surgery) to shrink the tumour.
- Adjuvant: treatment given after the main treatment to lower the chance of the cancer coming back.
- Resectable / borderline resectable / unresectable: whether a surgeon can remove the tumour completely, possibly with difficulty, or not at all.
- Restaging: repeating scans after a phase of treatment to see how the tumour has responded.
- Best supportive care: focusing on symptoms and comfort when further cancer-directed treatment isn’t expected to help.
- Re-discuss after…: the board wants the case brought back once a specific test or treatment phase is complete.
What Goes Into the Case Packet
Before a case reaches the board, someone, usually a junior doctor, fellow or nurse coordinator, prepares a short summary. Knowing what goes into it shows you why complete records matter. A typical packet includes:
- Age, sex and performance status (how active and fit the patient is, often scored on the ECOG scale from 0 to 4)
- Main symptoms and how long they’ve been present
- Other illnesses and current medications
- Pathology: tumour type, grade, biomarkers and margins after surgery
- Imaging: the key scans, loaded and ready for the radiologist to present
- Treatment so far, if any
- The specific question for the board, for example “Operable now, or treat first?”
- Patient preferences or constraints, such as wanting to preserve fertility, travel limits or financial concerns
If any of these are missing, the board may postpone its decision until they’re available. For international patients, the usual gaps are old imaging that can’t be loaded, missing biomarker results and an unclear account of previous treatment.
How Tumour Boards Work Across Indian Hospitals
India’s cancer care system ranges from large government cancer institutes to private multispecialty hospital groups and standalone oncology centres. Tumour board practice varies across them:
- Large dedicated cancer centres typically run separate, frequent boards for each cancer type, with subspecialist pathologists and radiologists.
- Major private hospital groups usually hold weekly site-specific boards at their flagship cancer centres. Some link several branches by video.
- Smaller hospitals may hold a combined general oncology board, or present selected cases to virtual boards run by larger networks such as the National Cancer Grid.
None of these models is automatically better or worse for every patient. A smaller hospital that discusses your case carefully may serve you better than a large one where your case gets two rushed minutes. Asking how your case will be discussed is more useful than relying on the size of the institution.
Helping the Board Help You: Tips for Patients and Families
- Send complete, original-quality material. Scans as DICOM files, and slides and blocks for pathology review.
- Write down your priorities. For example: “I’d prefer to avoid a permanent stoma if there’s a reasonable alternative,” or “Being able to work matters to me.” Ask your doctor to pass these on to the board.
- Be honest about your health and circumstances. Heart problems, diabetes control, home support and financial limits all affect what’s realistic.
- Ask when the board meets so you know when to expect a decision.
- Ask for the outcome in writing, so you have it for future reference or a second opinion.
How Long Does It Take to Get a Board Decision?
For most patients, the board’s recommendation comes within one to two weeks of the full workup, but several factors can stretch or shorten that. Waiting for pathology review or molecular results is the most common delay. Board scheduling matters too: if your cancer type’s board meets on Thursdays and your last test result arrives on Friday, you may wait almost a week. Urgent cases, such as those causing compression of the spinal cord or airway, are usually discussed straight away or treated first and discussed afterwards. If you’re travelling for treatment, ask your coordinator for the expected board date before booking accommodation. It’s one of the simplest ways to avoid paying for extra nights while you wait.
Frequently Asked Questions
Can I attend my own tumour board meeting?
In most hospitals, no. The meetings are professional forums with many cases discussed quickly. A few centres are experimenting with patient participation. More commonly, your doctor meets you afterwards to explain the outcome.
Is there an extra fee for tumour board review?
In most Indian hospitals it’s part of standard cancer care and not billed separately. Some second-opinion services list “multidisciplinary review” as a paid package, so ask what’s included.
How soon after diagnosis is a case discussed?
Usually at the next scheduled board for that cancer type, once the key tests are complete. That’s often within one to two weeks of the full workup.
Can a tumour board change my diagnosis?
It can if the pathologist or radiologist on the board reinterprets the material, or if new information comes to light. More often, the board refines the stage and treatment sequence.
What if the board’s recommendation differs from what my surgeon told me?
Ask for a joint explanation. The board reflects several viewpoints, and your surgeon should be able to explain why the group reached its conclusion.
Do smaller hospitals have tumour boards?
Many do, sometimes in a simpler form. Others link to virtual boards run by larger centres. It’s always fair to ask.
This article is for general information. Tumour board practices vary between hospitals. For help finding a cancer centre in India with structured multidisciplinary review, contact HealthcheckBox.